Strs Ohio boosted its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 32.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 184,600 shares of the biopharmaceutical company’s stock after buying an additional 44,700 shares during the period. Strs Ohio owned approximately 0.46% of Emergent Biosolutions worth $5,820,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FIL Ltd purchased a new position in Emergent Biosolutions during the second quarter worth approximately $16,063,000. Mesirow Financial Investment Management Equity Management purchased a new position in Emergent Biosolutions during the second quarter worth approximately $15,439,000. Vanguard Group Inc. boosted its position in Emergent Biosolutions by 13.0% in the second quarter. Vanguard Group Inc. now owns 3,610,132 shares of the biopharmaceutical company’s stock worth $101,517,000 after buying an additional 415,470 shares during the period. Numeric Investors LLC purchased a new position in Emergent Biosolutions during the second quarter worth approximately $10,765,000. Finally, Aberdeen Asset Management PLC UK boosted its position in Emergent Biosolutions by 50.3% in the second quarter. Aberdeen Asset Management PLC UK now owns 725,018 shares of the biopharmaceutical company’s stock worth $20,387,000 after buying an additional 242,766 shares during the period. Institutional investors own 89.48% of the company’s stock.

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Emergent Biosolutions, Inc. (NYSE:EBS) opened at 30.66 on Friday. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 29.03 and a beta of 1.01. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $44.38. The company has a 50-day moving average price of $31.55 and a 200 day moving average price of $29.66.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.32. The firm earned $142.91 million during the quarter, compared to analysts’ expectations of $112.30 million. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. Emergent Biosolutions’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.93 EPS. On average, equities research analysts predict that Emergent Biosolutions, Inc. will post $1.05 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this story can be accessed at http://www.watchlistnews.com/strs-ohio-increases-stake-in-emergent-biosolutions-inc-ebs/1061378.html.

EBS has been the topic of a number of recent research reports. Wells Fargo & Company reaffirmed a “positive” rating and set a $41.00 price objective on shares of Emergent Biosolutions in a research report on Friday, September 30th. Zacks Investment Research lowered Emergent Biosolutions from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 5th. Chardan Capital reaffirmed a “buy” rating and set a $47.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, November 9th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Emergent Biosolutions in a research report on Monday, January 9th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $39.40.

In other Emergent Biosolutions news, Director Ronald Richard sold 5,900 shares of Emergent Biosolutions stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $34.09, for a total value of $201,131.00. Following the transaction, the director now owns 19,870 shares in the company, valued at approximately $677,368.30. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Daniel Abdun-Nabi sold 28,240 shares of Emergent Biosolutions stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $31.28, for a total transaction of $883,347.20. Following the completion of the transaction, the insider now owns 172,945 shares in the company, valued at approximately $5,409,719.60. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by company insiders.

About Emergent Biosolutions

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

5 Day Chart for NYSE:EBS

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.